Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host its first R&D Day for investors and analysts in New York City on Friday, March 29, 2019, beginning at 8:30 a.m. ET.
NEW YORK and BASEL, Switzerland, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host its first R&D Day for investors and analysts in New York City on Friday, March 29, 2019, beginning at 8:30 a.m. ET.
Axovant’s chief executive officer, Pavan Cheruvu, MD, will provide opening remarks and Gavin Corcoran, MD, executive vice president of R&D, will moderate the event. The agenda for R&D Day will include development updates, scientific and clinical insights from prominent physicians and researchers, and patient perspectives across Axovant’s gene therapy pipeline. Invited guest speakers for each program include:
AXO-Lenti-PD for Parkinson’s disease
- C. Warren Olanow, MD, FRCPC, FRCP (hon), Mount Sinai School of Medicine
- Stéphane Palfi, MD, PhD, Assistance Publique - Hôpitaux de Paris
AXO-AAV-GM1 and AXO-AAV-GM2 for GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases
- Terence Flotte, MD, University of Massachusetts Medical School
- Heather Gray-Edwards, DVM, PhD, University of Massachusetts Medical School
- Douglas Martin, PhD, Auburn University
AXO-AAV-OPMD for Oculopharyngeal Muscular Dystrophy
- Guy Rouleau, OQ, MD, PhD, FRCP, FRSC, Montreal Neurological Institute & Hospital
Axovant’s Scientific Advisory Board
- Chairman, Michael Hayden, MB ChB, PhD, University of British Columbia
The event will be webcast live under the investor relations section of Axovant’s website atwww.axovant.com. An archived webcast will be available on Axovant’s website for 30 days following the event.
About Axovant
Axovant Sciences is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.
Contacts:
Media
Mike Beyer
Sam Brown Inc.
(312) 961-2502
mikebeyer@sambrown.com
media@axovant.com
Investors
Tricia Truehart
Axovant
(631) 892-7014
investors@axovant.com
